Most Read Articles
Jairia Dela Cruz, 10 Apr 2019
Treatment with tofacitinib yields significant improvements in signs and symptoms of rheumatoid arthritis (RA) in patients from the Asia Pacific, according to data from a posthoc analysis. The drug has a safety profile consistent with global tofacitinib studies, although infections occur more frequently in Asians.
Jairia Dela Cruz, 30 Apr 2019
In rheumatoid arthritis (RA) patients in remission, increasing the dose interval of tocilizumab injection from the standard 162 mg once weekly to twice weekly may do more harm than good. Specifically, such a strategy is associated with a lower chance of remission maintenance as well as a lack of improvement in tolerability, as shown in a recent trial.
Jairia Dela Cruz, 29 Apr 2019
Physicians are likely to underestimate the severity of psoriatic arthritis (PsA) in patients who are older, show higher fatigue levels, complain of greater pain or have poorer mental health, according to a Singapore study. In contrast, overestimation of disease severity by physicians tends to occur in the presence of higher swollen joint counts.
16 Apr 2019
New drug applications approved by US FDA as of 01 - 15 April 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Increased faecal calprotectin signals worse disease activity in axial spondyloarthritis

06 Feb 2019

Gut inflammation, as indicated by elevated faecal calprotectin levels, may be a marker of more severe disease in patients with axial spondyloarthritis (axSpA), according to data from the SPARTAKUS cohort. Specifically, increased calprotectin levels are associated with worse disease activity and physical function.

Researchers analysed the association of faecal calprotectin levels and the presence of anti-Saccharomyces cerevisiae antibodies (ASCA) in serum with disease subtype and current status in consecutive patients with a clinical axSpA diagnosis, which was classified as nonradiographic (nr-axSpA; n=40) or ankylosing spondylitis (AS; n=90), and in healthy controls (n=35).

Faecal calprotectin levels were elevated (50 mg/kg) in 27 percent of nr-axSpA patients, 38 percent of AS patients and 6 percent of controls. Of note, the levels were significantly higher in AS vs nr-axSpA patients (geometric mean, 41 vs 24 mg/kg; p=0.037) and in each axSpA subtype vs controls.

Overall, axSpA patients with elevated vs normal F-calprotectin levels showed worse disease activity and physical function scores, with marked differences in the visual analogue scale for global health, Ankylosing Spondylitis Disease Activity Score using C-reactive protein, and the Bath AS Functional.

Meanwhile, ASCA titres and seropositivity (10 U/ml) were similar in the nr-axSpA (IgA/IgG-seropositivity: 8 percent and 26 percent, respectively) and AS (IgA/IgG-seropositivity: 7 percent and 28 percent, respectively) cohorts. Clinical outcome measures did not significantly differ between patients with elevated vs normal ASCA IgA or IgG.

Compared with controls, patients in both axSpA subtypes had significantly greater ASCA IgA, while those in the AS group had markedly increased ACSA IgG.

The present data are in line with previous observations of more pronounced sacroiliitis in patients with microscopic gut inflammation, thus providing further evidence of an important interplay between gastrointestinal and musculoskeletal manifestations of axSpA, as researchers pointed out.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 10 Apr 2019
Treatment with tofacitinib yields significant improvements in signs and symptoms of rheumatoid arthritis (RA) in patients from the Asia Pacific, according to data from a posthoc analysis. The drug has a safety profile consistent with global tofacitinib studies, although infections occur more frequently in Asians.
Jairia Dela Cruz, 30 Apr 2019
In rheumatoid arthritis (RA) patients in remission, increasing the dose interval of tocilizumab injection from the standard 162 mg once weekly to twice weekly may do more harm than good. Specifically, such a strategy is associated with a lower chance of remission maintenance as well as a lack of improvement in tolerability, as shown in a recent trial.
Jairia Dela Cruz, 29 Apr 2019
Physicians are likely to underestimate the severity of psoriatic arthritis (PsA) in patients who are older, show higher fatigue levels, complain of greater pain or have poorer mental health, according to a Singapore study. In contrast, overestimation of disease severity by physicians tends to occur in the presence of higher swollen joint counts.
16 Apr 2019
New drug applications approved by US FDA as of 01 - 15 April 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.